Endometrial cancer is the most common gynecological cancer in the United States. Research efforts in this disease have focused on identifying key genetic aberrations such as somatic mutations, but no effective targeted therapies have been established. By contrast, "mutations" at the RNA level caused by RNA editing, an important epigenetic control, have received little attention in endometrial cancer and indeed, cancer in general. To date, the importance of individual RNA editing events has been documented in several cancer types;however a comprehensive investigation has not been attempted in any cancer type. Strikingly, the preliminary analyses by this research team reveal that the overexpression of major RNA editing enzymes significantly correlates with poor patient survival in endometrial cancer. The long-term goal is to elucidate the role of RNA editing in the pathophysiology of endometrial cancer and develop novel biomarkers or treatment strategies. The current objective is to systematically identify "driver" RNA editing events and elucidate their associated mechanisms in this disease. The central hypothesis is that some RNA editing events play a crucial role in the initiation and progression of endometrial tumors. The rationale is that the key RNA-editing-induced nucleotide changes identified will represent promising biomarkers or therapeutic targets for endometrial cancer and such a study will have major impacts across the breadth of oncology. Guided by strong preliminary data, this hypothesis will be tested by pursuing two specific aims:
Aim 1. Detect RNA editing sites associated with tumor over-editing activity or clinical variables in endometrial cancer. The Cancer Genome Atlas (TCGA) sequencing data will be analyzed to identify RNA editing sites that have significant over-editing activity in endometrial tumors or correlate with important clinical variables. The observed patterns of RNA editing will then be validated using orthogonal approaches in both TCGA samples and a large, independent, in-house cohort of endometrial tumor samples. The preliminary results have demonstrated a substantial number of such RNA editing sites.
Aim 2. Identify driver RNA editing events in the pathogenesis of endometrial tumors. The functional impact of RNA editing events identified in Aim 1 will be examined through a novel two-step functional assessment strategy using highly sensitive cell viability assays. The genomic aberrations associated with these editing events will be determined through disequilibrium analyses on TCGA/in-house genomics data. For the RNA editing driver events, functional proteomics in selected endometrial tumor cell lines will be used to identify their affected signaling pathways. This project is innovative because it represents a systematic approach to identifying key epigenetic changes as the molecular basis of endometrial cancer. It is significant because the knowledge gained will vertically advance the understanding of endometrial tumorigenesis and facilitate the development and implementation of a novel class of biomarkers or therapeutic targets. In addition, the computational and experimental methods established will be readily applicable to other cancer types.

Public Health Relevance

The proposed research is relevant to public health because the functional characterization of RNA editing is expected to increase the molecular-level understanding of the pathogenesis and cellular mechanisms of endometrial cancer, thereby helping the development of novel biomarkers or therapies that target this disease. Thus, this project is relevant to the NIH's mission to develop fundamental knowledge that will help to reduce the burdens of human disability.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
1R01CA175486-01A1
Application #
8630743
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Strasburger, Jennifer
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Biostatistics & Other Math Sci
Type
Hospitals
DUNS #
City
Houston
State
TX
Country
United States
Zip Code
77030
Yuan, Yuan; Van Allen, Eliezer M; Omberg, Larsson et al. (2014) Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol 32:644-52